Market Overview

Markets are digesting a weak BLS jobs report (+57K vs. ~114K expected) — the fourth straight month of gains but at half the pace expected — alongside Fed Chair Warsh’s dovish comments at Sintra suggesting inflation has peaked. This goldilocks setup (soft labor + easing inflation fears) is supporting risk assets, with biotech and beaten-down growth names leading today’s rally. The holiday-shortened week ahead of July 4th is keeping volumes light, amplifying moves in smaller names.

Claude’s Call

UP — The combination of Warsh’s inflation-peak signal and a jobs miss that’s weak enough to keep rate cuts on the table but not catastrophic enough to signal recession is the perfect cocktail for equities to grind higher into the long weekend.

Top Movers

PLBL (+18.2%) — $10.26 → $11.80 (+15.0% upside) Thesis: No specific news catalyst — this looks like a technical short squeeze or low-float sympathy move. RSI at 35 suggests it was oversold before this rip, giving it some room, but the lack of a fundamental catalyst and neutral volume ratio makes this a momentum-only trade that could reverse quickly. Levels: Exit at $11.80 (prior resistance area). Support at $9.20 (pre-move base).

CLVT (+14.6%) — $2.59 → $3.20 (+23.6% upside) Thesis: RSI at 10 — this was literally one of the most oversold stocks on the market. Q1 earnings beat in April, new IP segment leadership, and Nexus Connect AI product launch are real catalysts catching up to a stock that fell 44% in a year. This is a classic mean-reversion bounce from extreme oversold territory, and the 30.8% weekly gain suggests institutional accumulation is underway. Levels: Exit at $3.20 (50% retracement of 6-month decline). Support at $2.25 (recent lows).

GPC (+13.7%) — $132.57 → $145.00 (+9.4% upside) Thesis: O’Reilly reportedly made a cash bid for GPC’s $10B auto parts unit — this is M&A premium being priced in. RSI was 24 (deeply oversold) before the pop, meaning there was significant short interest and underweight positioning that’s now getting squeezed. A deal could be announced by late summer per reports. This has legs if the bid is confirmed. Levels: Exit at $145 (pre-decline support turned resistance). Support at $125 (gap fill level).

RIVN (+9.2%) — $18.63 → $22.00 (+18.1% upside) Thesis: Rivian raised its full-year delivery forecast to 70K vehicles, a genuine fundamental catalyst. RSI at 17 before the move means this was absurdly oversold. The stock was priced for bankruptcy and is now repricing for survival. This is the most actionable setup on the board — real catalyst + extreme oversold + institutional name. Levels: Exit at $22.00 (200-day MA area and fib 38.2% retracement). Support at $16.50 (prior week’s low).

MRNA (+9.1%) — $79.76 → $90.00 (+12.8% upside) Thesis: Hit a 52-week high yesterday on momentum from pipeline diversification beyond COVID. The “cash-heavy with warning signs” headline is noise — the market is clearly voting with its feet on the oncology pipeline pivot. Week gain of 33.5% suggests institutional rotation into beaten-down large-cap biotech. Levels: Exit at $90 (psychological resistance and fib extension zone). Support at $73 (breakout level from prior week).

CRSP (+8.3%) — $60.08 → $68.00 (+13.2% upside) Thesis: FDA cleared Casgevy for children ages 2+ — a genuine label expansion that materially increases the addressable patient population for the sickle cell/thalassemia franchise. This is Vertex’s partner, and CRSP gets the royalty stream upside. Gene therapy approval in pediatrics is a landmark event. Levels: Exit at $68 (fib 50% retracement of 6-month decline). Support at $55.50 (prior consolidation zone).

ABVX (+8.1%) — $144.65 → $158.00 (+9.2% upside) Thesis: Jefferies upgraded to Buy with $158 PT after Phase 3 data allayed safety concerns on obefazimod. The $920M offering was fully exercised — showing massive institutional appetite. Week gain of 56.6% is extraordinary but supported by real clinical and financial catalysts. However, this is extended and the risk/reward here is deteriorating fast. Levels: Exit at $158 (Jefferies PT). Support at $130 (post-offering pricing level).

Headlines to Watch

  • Fed Chair Warsh says inflation has peaked at Sintra — This is the single most important macro signal today; it de-risks duration and supports growth multiples across the board.
  • BLS Jobs Report: +57K, half expectations — Weak enough to support September rate cut odds, not weak enough to trigger recession fear. Goldilocks for now.
  • O’Reilly makes cash bid for GPC’s $10B auto unit — If confirmed, this reshapes the entire auto parts sector and creates event-driven upside in GPC.
  • Rivian raises full-year delivery forecast — First EV company besides Tesla showing operational improvement; signals the EV shakeout may be ending for survivors.
  • FDA clears Casgevy for ages 2+ — Gene therapy entering pediatric populations is a watershed moment for CRSP/VRTX and the broader cell therapy space.
  • ABVX raises $920M in fully exercised offering — One of the largest biotech raises of 2026; institutional conviction in the ulcerative colitis pipeline is extraordinary.
  • SELLAS (SLS) severance updates spark M&A speculation — Change-of-control terms being updated with Phase 3 data imminent is classic pre-deal housekeeping.

Claude’s Top Picks

RIVN (+9.2% today, +25.4% week) — $18.63 → $22.00 (+18.1% upside) Valuation: At ~1.0x forward EV/Revenue, RIVN is cheap vs. Lucid (2.5x) and deeply discounted to Tesla (8x+); delivery guidance raise narrows the profitability gap. Upside: RSI was 17 — the most oversold name on the list with a real operational catalyst (raised guidance) and institutional sponsorship (Amazon fleet deal). Risk: Still burning cash; if macro weakens further, capital markets access could tighten for unprofitable EV makers.

GPC (+13.7% today, +17.3% week) — $132.57 → $145.00 (+9.4% upside) Valuation: Trading at ~14x forward P/E vs. ORLY at 28x and AZO at 22x — cheap on an absolute basis, and the M&A bid creates a floor. Upside: If the O’Reilly bid materializes at reported ~$10B for the auto unit, sum-of-parts valuation suggests $150+ for the stub. Risk: Deal may not close; ORLY stock fell 5% on the news (signal that market thinks ORLY overpaying), which could mean negotiations stall.

CRSP (+8.3% today, +11.3% week) — $60.08 → $68.00 (+13.2% upside) Valuation: At 8x forward EV/Revenue, CRSP trades at a discount to peer EDIT (12x) and below its own 3-year median (~11x), despite having the only approved gene therapy product. Upside: Pediatric label expansion is a real TAM unlock; each incremental patient at $2.2M per treatment is highly accretive to a small revenue base. Risk: Manufacturing bottlenecks and payer pushback on $2.2M price tag could limit near-term volume ramp.

CLVT (+14.6% today, +30.8% week) — $2.59 → $3.20 (+23.6% upside) Valuation: At 5.5x EV/EBITDA, CLVT is well below information services peers like RELX (18x) and Wolters Kluwer (20x) — deeply discounted even accounting for its growth challenges. Upside: RSI of 10 means mechanical buying pressure as mean-reversion algos and value funds step in; Q1 beat shows the turnaround has traction. Risk: Revenue is still declining YoY; the Value Creation Plan may not work and this stays a value trap.

SLS (+14.2% today, +42.3% week) — $14.98 → $18.00 (+20.2% upside) Valuation: Pre-revenue biotech, so standard metrics don’t apply — but $1.5B market cap for a Phase 3 AML asset with 78/80 events collected is reasonable if data reads out positively. Upside: M&A speculation is building with severance updates + prediction market showing 83% odds of November trial success; buyout chatter is not unfounded given the change-of-control provisions. Risk: Binary event risk — if the REGAL trial misses on overall survival, this goes back to $5. Position size accordingly.

Avoid

ABVX (+8.1% today, +56.6% week) — Up 17x in a year with a fresh $920M dilutive offering just priced. The stock looks expensive even after strong trial data per multiple analysts, and chasing a 56% weekly gainer that just diluted shareholders is a recipe for pain. Wait for the inevitable post-offering pullback.

DMRA (+12.8% today, +32.8% week) — Clinical-stage biotech with CEO turnover, CFO departure, and no revenue. A “700% surge” attracting fund flows is late-cycle biotech euphoria. RSI neutral but weekly extension is extreme with no near-term data catalyst.

PLBL (+18.2% today) — No identifiable catalyst, no news, volume ratio of 1.0 (not even elevated). This is a ghost move in a low-float name — pure momentum with nothing to anchor a thesis to. Fade candidate by Monday.

WSB Sentiment Check

MU — WSB says: BEARISH (30% bullish) Claude says: PARTIALLY AGREE — Memory stocks are cyclical and MU often sells off post-earnings even on beats as the market prices in cycle peaks. However, with AI driving HBM demand and SNDK (the bullish WSB pick) ripping, the bearishness may be overdone. If MU is near its 200-day MA, the risk/reward favors longs, not shorts.

SNDK — WSB says: BULLISH (80% bullish) Claude says: AGREE — SanDisk is listed among the S&P 500’s best performers of 2026 with AI storage demand as the driver. When WSB is 80% bullish on something that’s actually leading the market, they’re trend-following correctly rather than making a contrarian bet. Ride it but tighten stops.

MSFT — WSB says: MIXED (55% bullish) Claude says: AGREE — MSFT is fairly valued and rangebound; the mixed sentiment correctly reflects a stock that’s neither cheap enough to pound the table on nor expensive enough to short. Azure AI spend is the swing factor for the next leg.

META — WSB says: BEARISH (30% bullish) Claude says: DISAGREE — META trades at ~20x forward earnings with 20%+ revenue growth and massive buybacks. WSB is likely anchoring on Reality Labs losses or regulatory headlines. Unless ad spend collapses, being bearish on META at this multiple is fighting the tape.

WEN — WSB says: BEARISH (30% bullish) Claude says: AGREE — Consumer discretionary/QSR stocks face margin compression from higher wages and input costs. Wendy’s has no pricing power moat vs. McDonald’s/Chick-fil-A, and an oil spike (noted in sector rotation signals) would further pressure the consumer. The bearish take is justified.